Arcadia Biosciences Inc risk profile
56 Elevated one input has moved against it
Measured 21 October 2026 from RKDA's filed statements. Recomputed nightly.
56 (Elevated), driven by Concentration at 100, over 7 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 83 | Acute | Volatile | One-year price volatility — 97.9% |
| Operating pressure | 5 | Contained | Easing | Input-cost exposure — 0.11 |
| Cash conversion | 57 | Elevated | Easing | Free-cash-flow margin — -96.7% |
| Leverage and coverage | 6 | Contained | Stable | Current ratio — 3.09x |
| Competitive position | 85 | Acute | Stable | Operating-margin gap against peers — -44.8 percentage points |
| Concentration | 100 | Acute | Stable | Geographic concentration — 10,000 HHI |
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Consumer Defensive companies with a risk reading
Walmart Inc 51Costco Wholesale Corp 44Coca-Cola Company 39Procter & Gamble Company 30Philip Morris International Inc 24Nestle S.A. 46Nestlé S.A 47L'Oréal S.A. 38PepsiCo Inc 49Anheuser-Busch InBev SA/NV 36Unilever plc 45Unilever PLC 35
Financials, valuation and price history for Arcadia Biosciences Inc